Zevra Therapeutics, Inc. valuation and forecast
Explore the models for Zevra Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.
Your valuation workspace
What is ZVRA worth to you?
Start with the company's financial data. Make the assumptions your own.
01 / Assumptions
Follow the forecast
The cash flows behind your value
View annual figures
| Forecast year | Cash flow / share |
|---|
Negative cash flows are shown in terracotta. Before the terminal value and equity bridge. Residual-income models show excess earnings; dividend models show dividends.
See the range of possibilities
Compare and combine your models
Weights start with the platform's included models. Change them to build your own combination. Select a model name to edit its assumptions.
| Model | Your value / share | Weight |
|---|
The platform's price and consistency filters are not reapplied to your scenarios.
Other model types 15 unavailable for ZVRA
Justified price-to-book
return on equity is not positive
Cash-flow DCF
This model does not apply to this company with the available financial data.
P/B vs return on equity
This model does not apply to this company with the available financial data.
Peer price-to-book
This model does not apply to this company with the available financial data.
Peer P/E
This model does not apply to this company with the available financial data.
Peer price-to-FFO
This model does not apply to this company with the available financial data.
Peer price-to-sales
This model does not apply to this company with the available financial data.
PEG comparison
This model does not apply to this company with the available financial data.
Two-stage dividend discount
This model does not apply to this company with the available financial data.
Growing-dividend model
This model does not apply to this company with the available financial data.
REIT funds from operations
This model does not apply to this company with the available financial data.
Utility earnings
This model does not apply to this company with the available financial data.
Book value / net assets
This model does not apply to this company with the available financial data.
Reported crypto treasury NAV
This model does not apply to this company with the available financial data.
Proved-reserve NAV
This model does not apply to this company with the available financial data.
Model values are estimates under the assumptions shown. They are not share-price forecasts or investment advice.
Valuation models compared
Different models answer different questions: the cash-flow models ask what the business generates for owners; the peer multiples ask what similar companies in our coverage trade on. Where they disagree, the gap is the story. Projections are estimates based on current data, updated daily. Not investment advice. How each model works.
Analyst recommendations
Monthly trend
- Oct 20269
- Sep 20269
- Aug 20269
- Jul 20269
Counts of recommendations published by analysts covering Zevra Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
How our value has changed
View the data
| Period | Our value per share |
|---|---|
| FY2021 Q4 (backtest) | $6.20 |
| FY2022 Q1 (backtest) | $4.82 |
Our model re-run on each past quarter's filed figures: how the method would have valued Zevra Therapeutics, Inc. at the time (a backtest — our dated public record starts at launch). The grey line is the share price at month end, for comparison.
ZVRA valuation questions
- How does Fundamentalytics value Zevra Therapeutics, Inc.?
- We use the models that fit Zevra Therapeutics, Inc.'s business and available financial data: growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved October 29, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Zevra Therapeutics, Inc.